NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Tags: Keytruda


Reuters rehashes Merck announcement on Keytruda trial for esophageal cancer


Immunotherapy’s ‘new era:’ LA Times story overlooks the risks and overstates trial results


Keytruda for bladder cancer: No independent scrutiny of Merck-reported results


Reuters’ ‘New day in lung cancer’ presents overly rosy picture of Keytruda

1 6/22/2016

NBC News takes level-headed approach covering ‘Jimmy Carter drug’ for lung cancer


Except for presidential anecdote, NBC story on new melanoma drug was well-balanced

5 10/28/2015

News release-based story on cancer drug lacks most of what readers need


Keytruda and colon cancer: coverage of benefits not balanced with harms and cost info